Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
The drug industry's need to improve product quality while reducing production costs is driving global demand for testing technologies according to Sepha.
Chemicals supplier Lonza will manufacture the API for a candidate Alzheimer’s disease drug being developed by Elan in an agreement announced yesterday.
The USP has forged closer bonds with the Chilean Pharmacopoeia Foundation (CPF) in the latest of a series of agreements with regional drug quality groups.
Almac says growing demand for non-GMP manufacturing work rather than competition was the key driver for expansion of its product development services business.
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Recapturing customers will not be easy for Albany Molecular Research (AMRI) after the problems at its manufacturing plant in Burlington, Massachusetts according to an analyst.
Greater FDA oversight of US manufacturing plants increased the number of drug recalls in Q3 in a trend that is likely to continue according to a new report.
Piramal Healthcare has added commercial-scale antibody-drug-conjugate (ADC) manufacturing capacity at its UK plant predicting increasing demand for this specialist type of contracting.
Gains made in manufacturing, particularly in biologics, were pegged back by the impact raw materials costs and the strong Franc had on its ingredients division says Lonza.
Retrofitting stainless steel plants with single-use systems is driving a “paradigm shift” in drug production but creates logistical problems, an AAPS panel said.
Multinational biotech giant, Lonza, has completed the acquisition of US-based Arch Chemicals as the company bids to tap into the microbial control sector.
3M, the US-headquartered multinational, has launched a new range of bio filters which it says raise the benchmarks for flow-rate, organism reduction and efficiency across a range of applications.
Almac hopes adding high potency API manufacturing capacity at its plant in Craigavon, Northern Ireland will help it retain early phase projects as they move to late-stage development.
